Resources

Lung Cancer Resources

You’re not alone

We give you more than information; we can also connect you with people who know what you're going through and are there to help.

Guide to understanding TAGRISSO

Download the brochure about TAGRISSO, a major advancement in lung cancer.

Download the brochure

Also available in other languages:
Chinese | Spanish | Vietnamese

Sign up for a free information kit on diagnosis and treatment.

Information and tools from lung cancer advocacy organizations

Understanding Non-Small Cell Lung Cancer

Learn more about NSCLC

The Lung Cancer Alliance has information about NSCLC, diagnostic testing, and types of treatments.

Learn more now
Create a lung cancer care plan

Create a lung cancer care plan

My Lung Cancer Care Plan, developed by Free to Breathe, is helpful for discussions with your doctors. You can keep track of information about your diagnosis, treatments, doctor appointments, and symptoms.

Download now
Download the Lung Cancer Navigator mobile app by LUNGevity

Get an app to support you throughout your journey

The Lung Cancer Navigator by LUNGevity is a customizable mobile app that helps you understand your condition, get answers to your questions, and manage your medications. Through the app, you can connect with your doctors and request support from loved ones.

Download the app

Lung cancer communities and organizations

LVNG With Lung Cancer is a community of people like you who are building each other up with encouragement and empowerment.
facebook.com/lvngwith
1-8-0-0-236-9933

The Bonnie J. Addario Lung Cancer Foundation is devoted to research, education, and making a meaningful change.
lungcancerfoundation.org
1-6-5-0-598-2857

The Lung Cancer Research Foundation has a mission to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.
lungcancerresearchfoundation.org
1-2-1-2-588-1580

Lung Cancer Alliance empowers the lung cancer community by helping people navigate the paths of early detection, diagnosis, and treatment.
lungcanceralliance.org
1-8-0-0-298-2436

The American Cancer Society offers a variety of programs and resources.
cancer.org
1-8-0-0-227-2345

GRACE, the Global Resource for Advancing Cancer Education, is committed to providing unique and helpful information to people with lung cancer.
cancergrace.org
1-8-8-8-501-1025

LUNGevity is changing outcomes for people with lung cancer through research, education, and support.
lungevity.org
1-8-4-4-360-5864

Frequently asked questions

What is EGFR?

EGFR, or epidermal growth factor receptor, is a type of protein found on the surface of cells in the body. But sometimes this protein changes or mutates and becomes too active. If it does mutate, that means certain cells are being told to grow and spread faster than they should. This leads to cancer. If your doctor finds the EGFR biomarker using a biopsy or a blood test, this means the EGFR mutation is driving your cancer growth.

What is EGFR+ lung cancer?

Non-small cell lung cancer with the EGFR biomarker is known as EGFR+ NSCLC. In the United States, approximately 10% of people with metastatic NSCLC have tumors that are positive for the EGFR biomarker.

What is EGFR+ lung cancer with the T790M mutation?

When a cancer treatment stops working, this may be because the tumors become resistant to the targeted therapy being used (often a tyrosine kinase inhibitor or TKI). If this happens, your lung cancer will grow or spread (which is known as progression).

When EGFR+ NSCLC becomes resistant to specific TKIs, it could be due to another mutation called T790M. Learn more

What is biomarker testing?

Testing for biomarkers is an important part of your lung cancer diagnosis. Biomarker testing is done as either a biopsy (where tissue is removed from a tumor so it can be tested) or a blood test (also known as a liquid biopsy). Your doctor will decide which test is right for you. Finding out which biomarker you have, such as EGFR, can help determine the treatment options that may give you the best results for your type of lung cancer. Biomarker testing is sometimes referred to as genetic testing, molecular testing, or mutation testing.

What is targeted therapy? How does it work?

Targeted therapies are treatments designed for specific types of lung cancer. They are not chemotherapy or immunotherapy. Targeted therapies help stop the growth and spread of cancer cells, and cause them to die.

What is TAGRISSO?

TAGRISSO is a prescription medicine for non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). TAGRISSO is used as a first treatment if tumors have a certain abnormal epidermal growth factor receptor (EGFR) gene(s).

Learn more about TAGRISSO for EGFR+ lung cancer.

Learn more about TAGRISSO for EGFR+ NSCLC that has become resistant to certain EGFR targeted therapies.

What are the side effects of TAGRISSO?

TAGRISSO may cause serious side effects, including:

  • lung problems. TAGRISSO may cause lung problems that may lead to death. Symptoms may be similar to symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever
  • heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded
  • eye problems. TAGRISSO may cause eye problems. Tell your doctor right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your doctor may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO

The most common side effects of TAGRISSO are:

  • diarrhea
  • rash
  • dry skin
  • changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails
  • mouth sores
  • tiredness
  • decreased appetite

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of TAGRISSO. For more information, ask your doctor or pharmacist.

What may TAGRISSO do for me?

TAGRISSO is a targeted therapy proven to work for 2 groups of people with metastatic NSCLC:

  • People diagnosed with EGFR+ lung cancer
    • In a clinical study, people taking TAGRISSO for EGFR+ lung cancer saw groundbreaking results and lived nearly twice as long without tumors growing or spreading compared with those taking erlotinib or gefitinib. The median time was 18.9 months for people taking TAGRISSO compared with 10.2 months for those taking erlotinib or gefitinib
  • See more results from a clinical study for TAGRISSO in EGFR+ lung cancer
  • People whose NSCLC has progressed and developed the T790M mutation after they took an EGFR targeted therapy other than TAGRISSO
    • In a clinical study, people taking TAGRISSO for EGFR+ lung cancer with the T790M mutation increased their chance of living without tumors growing or spreading by 70% compared with those receiving chemotherapy
  • See more results from a clinical study for TAGRISSO in EGFR+ lung cancer that has developed the T790M mutation

What should I tell my doctor before starting TAGRISSO?

Before taking TAGRISSO, tell your doctor about all of your medical conditions, including if you:

  • have lung or breathing problems
  • have heart problems, including a condition called long QTc syndrome
  • have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
  • have a history of eye problems
  • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant
    • Females who are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 6 weeks after the final dose of TAGRISSO
    • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the final dose of TAGRISSO
  • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your final dose of TAGRISSO. Talk to your doctor about the best way to feed your baby during this time

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your doctor if you take a heart or blood pressure medicine

Learn more

How do I take TAGRISSO?

TAGRISSO is a pill you take once a day. Take it with or without food, at the same time every day. Learn more

Are there any financial support programs for TAGRISSO?

AstraZeneca may be able to help you access the medicine you need. To find out more, visit MyAccess360.com or call 1-844-ASK-A360 (1-844-275-2360).

A disease in which abnormal cells divide out of control, at a very fast rate. These abnormal cells can spread to other nearby organs and tissues.

One of two main types of lung cancer. NSCLC is the most common.

A molecule that plays a role in many of the processes that happen in cells, such as skin and hair growth.

Any change in the DNA sequence of a cell. Mutations may be caused by mistakes during cell division or by exposure to DNA-damaging agents in the environment. They can be harmful, beneficial, or have no effect. Certain mutations may lead to cancer or other diseases.

A biological molecule found in blood, other body fluids, or tissues. A biomarker is a sign of a normal or abnormal process, or of a condition or disease. Biomarkers for NSCLC can include EGFR, ALK, PD-L1, BRAF, and ROS1. Testing for biomarkers is an important part of a complete lung cancer diagnosis.

Cancer that started in the lungs and has spread to other parts of the body such as the liver or brain. Often referred to as stage IV cancer.

An abnormal growth of cells that may be benign (not cancer) or malignant (cancer).

When cancer cells are no longer harmed by the drugs used to kill or disrupt them. Tumors can be resistant from the start of treatment or become resistant during the course of treatment.

A substance that prevents enzymes called tyrosine kinases from working. These enzymes are involved in the growth and division of cells, including cancer cells. TKIs are a type of targeted therapy.

When a therapy stops working and cancer cells grow or spread.

A mutation that develops in EGFR+ NSCLC and causes the cancer to become resistant to the treatment being used (often a tyrosine kinase inhibitor or TKI).

A cancer treatment that is designed to work specifically on the processes that cancer uses to grow rapidly and spread.

Drug therapy that can kill cancer cells or stop them from dividing.

Abnormal cells that divide at a very fast rate and spread throughout the body, interfering with normal cells and normal cell activity.

The middle number in a group of numbers arranged from lowest to highest.

A type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.

Important Safety Information

TAGRISSO may cause serious side effects, including:

  • lung problems. TAGRISSO may cause lung problems that may lead to death. Symptoms may be similar to symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever
  • heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded
  • eye problems. TAGRISSO may cause eye problems. Tell your doctor right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your doctor may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO
Important Safety Information

TAGRISSO may cause serious side effects, including:

  • lung problems. TAGRISSO may cause lung problems that may lead to death. Symptoms may be similar to symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever
  • heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded
  • eye problems. TAGRISSO may cause eye problems. Tell your doctor right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your doctor may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO

Before taking TAGRISSO, tell your doctor about all of your medical conditions, including if you:

  • have lung or breathing problems
  • have heart problems, including a condition called long QTc syndrome
  • have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
  • have a history of eye problems
  • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant
    • Females who are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 6 weeks after the final dose of TAGRISSO
    • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the final dose of TAGRISSO
  • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your final dose of TAGRISSO. Talk to your doctor about the best way to feed your baby during this time

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your doctor if you take a heart or blood pressure medicine

The most common side effects of TAGRISSO are:

  • diarrhea
  • rash
  • dry skin
  • changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails
  • mouth sores
  • tiredness
  • decreased appetite

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of TAGRISSO. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-fda-1088.

What is TAGRISSO?

TAGRISSO is a prescription medicine for non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). TAGRISSO is used:

  • as a first treatment if tumors have a certain abnormal epidermal growth factor receptor (EGFR) gene(s)
  • or
  • for a certain type of EGFR gene that has been treated with an EGFR tyrosine kinase inhibitor (TKI) medicine that did not work or is no longer working

Your doctor will perform a test to make sure that TAGRISSO is right for you.

It is not known if TAGRISSO is safe and effective in children.

Please see full Prescribing Information including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.